Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
“However,metforminmay lower risk for cardiovascular mortality compared with sulfonylurea therapy (100).”
BackgroundCellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, weight, and cardiovascular mortality (46); there is little systematic data available for other oral agents as initial therapy of type 2 diabetes.”
BackgroundChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“Metformin is the most commonly prescribed medication to treat T2DM, particularly in subjects with obesity (554).”
BackgroundClinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
“Metformin has also been shown to improve cardiovascular outcomes in patients with and without T2D, which can be attributed to increased vascular function, improved lipid profiles, and potentially, as a side effect of metformin-induced weight loss (2, 29-33).”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Microbiota and metabolic diseases
Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi, L., Govoni, S., Giustina, A., & Gazzaruso, C. (2018) · Endocrine · doi:10.1007/s12020-018-1605-5 · Cited by 423
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021) · Diabetology · doi:10.3390/diabetology2020004 · Cited by 323
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
“meta-analyses also support the first-line use of metformin for T2DM treatment.(7,8) Metformin has been used in Europe since 1957 and in the USA since 1994, subsequent to US Food and Drug Administra-”
ResultPharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
AMPK: Potential Therapeutic Target for Ischemic Stroke
Jiang, S., Li, T., Ji, T., Yi, W., Yang, Z., Wang, S., Yang, Y., & Gu, C. (2018) · Theranostics · doi:10.7150/thno.25674 · Cited by 232
“is the first-line oral medication for the treatment of type 2 diabetes [91, 92].”
BackgroundImpact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD)
Battineni, G., Sagaro, G. G., Chintalapudi, N., Amenta, F., Tomassoni, D., & Tayebati, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094798 · Cited by 208
“Metformin, a biguanide anti-hyperglycemic agent, represents the first drug in the treatment of overweight diabetes patients [61].”
BackgroundQaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-1860 · Cited by 207
Strain, W. D., Down, S., Brown, P., Puttanna, A., & Sinclair, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01035-9 · Cited by 194
“The treatments for type 2 diabetes with the greatest propensity for causing hypoglycaemia are insulin and the insulin secretagogues: sulphonylureas (SUs) and glinides.”
BackgroundResultInfluentialOsteoarthritis year in review 2020: biology
van den Bosch, M. H. J. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.10.006 · Cited by 190
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Lazarus, B., Wu, A., Shin, J.-I., Sang, Y., Alexander, G. C., Secora, A., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 167
Luo, F., Das, A., Chen, J., Wu, P., Li, X., & Fang, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0860-y · Cited by 163
Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes
Orkaby, A. R., Cho, K., Cormack, J., Gagnon, D. R., & Driver, J. A. (2017) · Neurology · doi:10.1212/wnl.0000000000004586 · Cited by 161
“73 m(2) (calculated using the Chronic Kidney Disease Epidemiology Collaboration(22) equation) were excluded, as this is a contraindication for metformin.(10) A measure of diabetes severity by hemoglobin A1c (HbA1c) was also required for entry into the cohort.”
BackgroundMethodNovel Insights into Diabetic Kidney Disease
Młynarska, E., Buławska, D., Czarnik, W., Hajdys, J., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810222 · Cited by 167
“Metformin is effective at lowering blood glucose and HbA1c levels, and has a lower risk for hypoglycemia compared to other glucose-lowering drugs [67,78,79].”
BackgroundPharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
“risk of hypoglycemia is lower with TZD, DPP4i, SGLT2i and GLP1RA compared to sulfonylureas and insulin (26-29,31,32,34,35).”
BackgroundInfluentialMetformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo
Han, J., Li, Y., Liu, X., Zhou, T., Sun, H., Edwards, P., Gao, H., Yu, F.-S., & Qiao, X. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193031 · Cited by 132
“Metformin could potentially serve this purpose due to its well-established safety and efficiency profile in early treatment of diabetes, as well as pleiotropic effects in cardiovascular and nephrovascular system [9, 11, 32].”
The role of adipokines in skeletal muscle inflammation and insulin sensitivity
Nicholson, T., Church, C., Baker, D. J., & Jones, S. W. (2018) · Journal of Inflammation · doi:10.1186/s12950-018-0185-8 · Cited by 126
“One of the major treatment strategies for T2D patients is to increase insulin sensitivity, either through lifestyle modifications such as weight loss, or via the administration of insulin-sensitising drug therapies including Biguanides such as Metformin [3, 4] and Thiazolidinediones [5].”
BackgroundMetformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis
Soberanes, S., Misharin, A. V., Jairaman, A., Morales-Nebreda, L., McQuattie-Pimentel, A. C., Cho, T., Hamanaka, R. B., Meliton, A. Y., Reyfman, P. A., Walter, J. M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.019 · Cited by 131
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
Sun, T., Liu, H., & Ming, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485285 · Cited by 125
Bu, Y., Peng, M., Tang, X., Xu, X., Wu, Y., Chen, A. F., & Yang, X. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17519 · Cited by 127
Prattichizzo, F., Giuliani, A., Mensa’, E., Sabbatinelli, J., Nigris, V. D., Rippo, M. R., Sala, L. L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.003 · Cited by 120
Strategies to Treat Obesity in Patients With CKD
Chintam, K., & Chang, A. R. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.016 · Cited by 118
“Leptogenic medications that result in neutral weight or weight loss include metformin, GLP-1 RAs, SGLT2 inhibitors, dipeptidyl peptidase-4 inhibitors, and pramlintide (63, 64).”
BackgroundRoeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 124
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 116
The wHole Story About Fenestrations in LSEC
Szafranska, K., Kruse, L. D., Holte, C. F., McCourt, P., & Zapotoczny, B. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.735573 · Cited by 90
Diabesity and antidiabetic drugs
Pappachan, J. M., Fernandez, C. J., & Chacko, E. C. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.10.004 · Cited by 108
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., & Thrailkill, K. M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 100
Gembillo, G., Ingrasciotta, Y., Crisafulli, S., Luxi, N., Siligato, R., Santoro, D., & Trifirò, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094824 · Cited by 113
“7 from RCTs in favor of metformin compared with sulfonylureas [81].”
BackgroundMetabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin
Yee, L. D., Mortimer, J. E., Natarajan, R. D., Dietze, E. C., & Seewaldt, V. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00058 · Cited by 113
The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Shi, Q., Cheng, Q., & Chen, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729101913 · Cited by 107
“As the first-line medicine for type 2 diabetes treatment [104], metformin may cause hypo-”
BackgroundEffects of phytochemicals against diabetes
Bacanli, M. G., DİLSİZ, S. A., Başaran, N., & Başaran, A. (2019) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2019.02.006 · Cited by 111
Lalau, J., Al‐Salameh, A., Hadjadj, S., Goronflot, T., Wiernsperger, N. F., Pichelin, M., Allix, I., Amadou, C., Bourron, O., Duriez, T., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101216 · Cited by 107
Conlin, P. R., Colburn, J., Aron, D., Pries, R. M., Tschanz, M. P., & Pogach, L. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1362 · Cited by 97
Metformin as Potential Therapy for High-Grade Glioma
Mazurek, M., Litak, J., Kamieniak, P., Kulesza, B., Jonak, K. E., Baj, J., & Grochowski, C. (2020) · Cancers · doi:10.3390/cancers12010210 · Cited by 94
Bidirectional causal associations between type 2 diabetes and COVID‐19
Cao, H., Baranova, A. V., Wei, X., Wang, C., & Zhang, F. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28100 · Cited by 94
“Consequently, T2D patients may demonstrate increased thirst, frequent urination, increased hunger, tired feeling, and sores that do not heal.(13) Complications of long‐term T2D”
BackgroundAntidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., & Kobayashi, D. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317519899546 · Cited by 89
“Multiple reports have shown that the use of sulfonylureas provides less favorable glycemic control than the use of other antidiabetic drugs.(20,38,53-55) A potential Figure 3.”
BackgroundMethodDiabetes and cirrhosis: Current concepts on diagnosis and management
Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 93
“[148,149] However, given the many factors promoting hypoglycemia in people with cirrhosis (Figure 3), including decreased appetite and cachexia, clinical judgment is needed if prescribed, but in general sulfonylureas should be avoided.[150] Finally, when the eGFR < 60 mL/min/1.”
BackgroundImpacts of the Human Gut Microbiome on Therapeutics
Vázquez-Baeza, Y., Callewaert, C., Debelius, J., Hyde, E., Marotz, C., Morton, J. T., Swafford, A., Vrbanac, A., Dorrestein, P. C., & Knight, R. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-042017-031849 · Cited by 79
Bergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Pleiotropic Effects of Metformin on Cancer
Schulten, H.-J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102850 · Cited by 88
“Based on its safety profile, MTF is the first-line antihyperglycemic drug for treatment of type 2 diabetes (T2D) which represents more than 90% of diagnosed diabetes [2,3].”
BackgroundSilveira, É. A., Vaseghi, G., Santos, A. S. E. A. D. C., Kliemann, N., Masoudkabir, F., Noll, M. A., Mohammadifard, N., Sarrafzadegan, N., & de Oliveira, C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239042 · Cited by 94
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 96
Okur, M. E., Karantas, I. D., & Siafaka, P. I. (2017) · ACTA Pharmaceutica Sciencia · doi:10.23893/1307-2080.aps.0555 · Cited by 131
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Phytochemicals and their effective role in the treatment of diabetes mellitus: a short review
Teoh, S. L., & Das, S. (2018) · Phytochemistry Reviews · doi:10.1007/s11101-018-9575-z · Cited by 83
Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125693 · Cited by 80
Non-alcoholic fatty liver disease in 2016
Townsend, S. A., & Newsome, P. N. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw031 · Cited by 74
Vazirpanah, N., Ottria, A., van der Linden, M., Wichers, C. G. K., Schuiveling, M., van Lochem, E. G., Phipps‐Green, A. J., Merriman, T. R., Zimmermann, M., Jansen, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214656 · Cited by 79
Medical Management of Diabesity: Do We Have Realistic Targets?
Pappachan, J. M., & Viswanath, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0828-9 · Cited by 80
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 75
Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Michailidis, M., Tata, D. A., Moraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094641 · Cited by 69
“due to its safe action profile (Figure 6) [62].”
BackgroundLi, Y., Ryu, C. L., Munie, M., Noorulla, S., Rana, S., Edwards, P. A., Gao, H., & Qiao, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2801450 · Cited by 78
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Scarpa, E. S., Antonelli, A., Balercia, G., Sabatelli, S., Maggi, F., Caprioli, G., Giacchetti, G., & Micucci, M. (2024) · Biomolecules · doi:10.3390/biom14070836 · Cited by 79
“…reported an increase in the use of natural products for the treatment of patients with T2DM [91–94]; this is due to the long-term use of insulin and oral hypoglycemic drugs, which are characterized by numerous side effects that include nausea, vomiting, diarrhea, and hepatorenal disorders [95].”
BackgroundCho, Y. K., Kang, Y. M., Lee, S. E., Lee, J. H., Park, J.-Y., Lee, W. J., Kim, Y. J., & Jung, C. H. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.011 · Cited by 70
Review article: new treatments in non‐alcoholic fatty liver disease
Townsend, S. A., & Newsome, P. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14210 · Cited by 66
“microvascular disease, myocardial infarction, large vessel disease, and cardiovascular mortality, in addition to aiding weight loss.(21) Although”
BackgroundPark, S. S., Perez, J. L. P., Gandara, B. P., Agudelo, C. W., Ortega, R. R., Ahmed, H., García‐Arcos, I., McCarthy, C., & Geraghty, P. M. (2022) · Medicina · doi:10.3390/medicina58081030 · Cited by 75
Ke, C., Stukel, T. A., Shah, B. R., Lau, E., Ma, R. C., So, W.-Y., Kong, A. P., Chow, E., Chan, J. C. N., & Luk, A. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003316 · Cited by 57
Metformin monotherapy for adults with type 2 diabetes mellitus
Gnesin, F., Thuesen, A. C. B., Kähler, L. K. A., Madsbad, S., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012906.pub2 · Cited by 62
Metformin: A Prospective Alternative for the Treatment of Chronic Pain
Baeza‐Flores, G. D. C., Guzmán‐Priego, C. G., Flores, L. I. P., Murbartián, J., Torres‐López, J. E., & Granados‐Soto, V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.558474 · Cited by 69
“…human beings after metformin administration (Tmax) is 1.5 to 2.7 h (Caillé et al., 1993; Sambol et al., 1996; Wei et al., 2009; Zhang et al., 2014; McCreight et al., 2018), which follows a multiphasic pattern (Graham et al., 2011), giving a peak plasma concentration (Cmax) of 1.1 to 2.5 µg/ml…”
BackgroundInfluentialKim, C., & Choi, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119607 · Cited by 65
Metformin inhibits SUV39H1-mediated migration of prostate cancer cells
Yu, T., Wang, C., Yang, J., Guo, Y., Wu, Y., & Li, X. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.28 · Cited by 64
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Ko, S., Hur, K.-Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Kim, H. J., Choi, K. M., & Kim, J. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.337 · Cited by 63
“If metformin is not tolerable or is contraindicated, the alternative choices for monotherapy include DPP4 inhibitors, SGLT2 inhibitors, TZDs, GLP-1RAs, SUs, glinides (meglitinide), α-glucosidase inhibitors (AGIs), and insulin according to patient circumstances (Table 2, Fig.”
InfluentialMetformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
Deng, M., Su, D., Xu, S., Little, P. J., Feng, X., Tang, L., & Shen, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00635 · Cited by 64
“This is mainly because of its high clinical value and low cost in controlling blood glucose (Maruthur et al., 2016).”
BackgroundRole of platelet-derived growth factor in type II diabetes mellitus and its complications
Shen, S., Wang, F., Fernandez, A., & Hu, W. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120942119 · Cited by 64
Zhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 73
Mu, W., Wang, Z., Ma, C., Jiang, Y., Zhang, N., Hu, K., Li, L., & Wang, Z. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.020 · Cited by 63
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
“Furthermore, hypoglycemia is more frequent with sulphonylureas than metformin (Maruthur et al., 2016).”
BackgroundLongato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 57
Sha’at, M., Spac, A., Stoleriu, I., Bujor, A., Cretan, M. S., Hartan, M., & Ochiuz, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061187 · Cited by 59
“Metformin used alone has been shown to reduce glycosylat d hemoglobin [9] by approximately 1.”
BackgroundBusch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57
“GLP-1RAs are generally well tolerated, with a characteristic AE profile that includes gastrointestinal AEs and injection-site reactions, particularly with the use of some once-weekly formulations [7,34,36,39], although injection-site reactions were rare with dulaglutide.”
BackgroundInfluentialBouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 60
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.